Multi-omics Landscape and Clinical Significance of a -driven Immune Signature: Implications for Risk Stratification and Frontline Therapies in Pancreatic Cancer
Overview
Authors
Affiliations
mutation was recently implicated in promoting invasion and poor prognosis of pancreatic cancer (PACA) by regulating the tumor immune microenvironment. However, -driven immune landscape and clinical significance remain elusive. In this study, we applied the consensus clustering and weighted correlation network analysis (WGCNA) to identify two heterogeneous immune subtypes and immune genes. Combined with -driven genes determined by mutation status, a -driven immune signature (SDIS) was developed in ICGC-AU2 (microarray data) via machine learning algorithm, and then was validated by RNA-seq data (TCGA, ICGC-AU and ICGC-CA) and microarray data (GSE62452 and GSE85916). The high-risk group displayed a worse prognosis, and multivariate Cox regression indicated that SDIS was an independent prognostic factor. In six cohorts, SDIS also displayed excellent accuracy in predicting prognosis. Moreover, the high-risk group was characterized by higher frequencies of / mutations and deletion, superior immune checkpoint molecules expression and more sensitive to chemotherapy and immunotherapy. Meanwhile, the low-risk group was significantly enriched in metabolism-related pathways and suggested the potential to target tumor metabolism to develop specific drugs. Overall, SDIS could robustly predict prognosis in PACA, which might serve as an attractive platform to further tailor decision-making in chemotherapy and immunotherapy in clinical settings.
Zhang X, Lin F, Wen Y, Guan K Discov Oncol. 2025; 16(1):96.
PMID: 39873820 PMC: 11775367. DOI: 10.1007/s12672-025-01841-8.
Sun Y, Hu C, Hu S, Xu H, Gong J, Wu Y Cancer Med. 2024; 13(21):e70388.
PMID: 39526476 PMC: 11551786. DOI: 10.1002/cam4.70388.
Xu H, Fu X, Liu B, Weng S, Guo C, Quan L iScience. 2023; 26(10):107871.
PMID: 37766999 PMC: 10520355. DOI: 10.1016/j.isci.2023.107871.
Wang Q, Xiong F, Wu G, Wang D, Liu W, Chen J Diagnostics (Basel). 2023; 13(17).
PMID: 37685308 PMC: 10487229. DOI: 10.3390/diagnostics13172769.
Systematic analysis of transcriptome signature for improving outcomes in lung adenocarcinoma.
Ge X, Xu H, Weng S, Zhang Y, Liu L, Wang L J Cancer Res Clin Oncol. 2023; 149(11):8951-8968.
PMID: 37160628 DOI: 10.1007/s00432-023-04814-y.